Therapeutic role of memantine for the prevention of cognitive decline in cancer patients with brain metastasis receiving whole-brain radiotherapy: a narrative review

ABSTRACT. Brain metastases are the most common central nervous system tumors. The mainstay treatment for this tumor in low to middle income countries is whole brain radiation therapy. Irreversible cognitive decline is associated with the use of whole brain radiotherapy. Several pharmacologic and non...

Full description

Bibliographic Details
Main Authors: Melmar Cerilo Folloso, Mazelle Torres, Stephen Lowell Ciocon, Jed Noel Ong, Jerickson Abbie Flores, Joseree-Ann Catindig
Format: Article
Language:English
Published: Associação Neurologia Cognitiva e do Comportamento 2022-05-01
Series:Dementia & Neuropsychologia
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642022005005201&lng=en&tlng=en
Description
Summary:ABSTRACT. Brain metastases are the most common central nervous system tumors. The mainstay treatment for this tumor in low to middle income countries is whole brain radiation therapy. Irreversible cognitive decline is associated with the use of whole brain radiotherapy. Several pharmacologic and nonpharmacologic options have been employed in studies focusing on the prevention of cognitive decline following whole-brain radiation therapy. Memantine use has been shown to provide some benefit in reducing the rate of decline in cognitive function and time to cognitive failure. The objective of this review article is to provide a summary on available primary literature on the therapeutic role of memantine for the prevention of cognitive decline in cancer patients with brain metastasis receiving whole brain radiotherapy.
ISSN:1980-5764